Skip to main content Back to Top
Advertisement

11/18/2022

Amoxicillin and Clavulanate Oral Presentations

Products Affected - Description

    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9981-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9981-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9981-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9982-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9982-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9982-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00143-9853-16
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00143-9853-24
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9853-75
    • Amoxicillin and Clavulanate oral tablet, Hikma, 875 mg/125 mg, 20 count, NDC 00143-9249-20
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 28 count, NDC 00781-1943-82
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 40 count, NDC 00781-1943-39
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6102-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 66685-1011-00
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 66685-1011-01
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6104-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 66685-1012-00
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 66685-1012-01
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00781-6139-54
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00781-6139-48
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6139-57
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 250 mg / 125 mg, 30 count, NDC 00781-1874-31
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 20 count, NDC 00781-1831-20
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 20 count, NDC 66685-1002-02
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 20 count, NDC 66685-1852-20
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 100 count, NDC 66685-1001-01
    • Amoxicillin and Clavulanate oral tablet, Teva, 400 mg/57 mg, 20 count, NDC 00093-2272-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 500 mg/125 mg, 20 count, NDC 00093-2274-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 875 mg/125 mg, 20 count, NDC 00093-2275-34

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • Hikma did not provide a reason for the shortage.
    • Morton Grove Pharmaceuticals and Micro Labs were not available to provide information.
    • Sandoz did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • US Antibiotics has amoxicillin and clavulanate oral suspension available.

Available Products

    • Amoxicillin and Clavulanate oral tablet, Teva, 200 mg/28.5 mg, 20 count, NDC 00093-2270-34
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 81964-0206-69
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 81964-0203-54
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 81964-0203-51

Estimated Resupply Dates

    • Hikma has amoxicillin and clavulanate oral presentations on allocation.
    • Sandoz has amoxicillin and clavulanate 200 mg/5 mL-28.5 mg/5 mL in 100 mL bottles and 600 mg/5 mL - 42.9 mg/5 mL in 200 mL bottles on back order and the company cannot estimate a release date. All other suspension presentations are in limited supply. The 500 mg/125 mg tablets in 100 count are on back order and the company cannot estimate a release date. All other oral tablets are in limited supply.
    • Teva has 200 mg/5 mL-28.5 mg/5 ml and 400 mg/5 mL-57 mg/5 mL in 100 mL bottles on back order and the company estimates a release date in late-November to early-December 2022. Short-dated product is available. The 600 mg/5 mL-42.9 mg/5 mL in all sizes are on back order and the company estimates a release date in mid- to late-November 2022. The 400 mg/57 mg tablets and 500 mg/125 mg tablets are on back order and the company estimates a release date in late-November to early-December 2022. The 875 mg/125 mg tablets are on back order and the company estimates a release date in early-January 2023.

Updated

Created November 18, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.